Preferences & Treatment Satisfaction Drivers in Rosacea Patients

Study Overview
=================
Brief Summary
-----------------
To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.

Official Title
-----------------
A Study of Patient Preferences and Drivers of Treatment Satisfaction in Patients With Rosacea

Conditions
-----------------
Rosacea

Intervention / Treatment
-----------------
* Drug: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)
* Drug: Azelaic Acid Cream
* Drug: Metronidazole gel
* Drug: Metronidazole cream
* Drug: Metronidazole Emulsion
* Drug: Metronidazole Lotion
* Drug: Brimonidine Tartrate Gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients of at least 18 years of age at index date At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3) At least 6 months of data history prior to the index date Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015 Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rosacea treated patients<br>Patients using topical rosacea treatment | Drug: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)<br>* Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser & Moisturizing<br>Drug: Azelaic Acid Cream<br>* Azelaic Acid Cream 20%<br>Drug: Metronidazole gel<br>* Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser<br>Drug: Metronidazole cream<br>* Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser<br>Drug: Metronidazole Emulsion<br>* Metronidazole Emulsion 0.75%<br>Drug: Metronidazole Lotion<br>* Metronidazole Lotion 0,75%<br>Drug: Brimonidine Tartrate Gel<br>* Brimonidine Tartrate Gel 0.33%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported concerns and importance of such concerns regarding their current topical rosacea treatments | Assessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely important | Rosacea treatment in the past 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported likelihood of switching to a topical rosacea treatments | Assessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all likely and 10 meaning extremely likely | Rosacea treatment in the past 4 weeks | 
| Quality of life | Measured using Dermatology Life Quality Index (DLQI): The DLQI consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatment | Rosacea treatment in the past 4 weeks | 
| Treatment satisfaction | Assessed by a score on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores will be standardized and expressed as a 0-100 standardized score | Rosacea treatment in the past 4 weeks | 
| Self-reported concerns and importance (a rating scale) of such concerns that patients would consider when switching to a new topical rosacea treatment | Extracted from the Rosacea Treatment Preference Questionnaire | Rosacea treatment in the past 4 weeks |